The CHIASMA OPTIMAL trial enrolled 56 acromegaly patients previously responsive to treatment with injected somatostatin receptor ligands and found that 58.2% of patients maintained an equivalent biochemical IGF-1 level and 77.7% maintained an equivalent GH level to that of an injectable somatostatin receptor ligand [25]. This evidence concerns the gene GH1 and acromegaly.